Trial ID or NCT#

NCT01997229

Status

recruiting iconRECRUITING

Purpose

The purpose of this study is to determine if eculizumab is safe and effective for the treatment of refractory generalized Myasthenia Gravis.

Official Title

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Eculizumab in Subjects With Refractory Generalized Myasthenia Gravis (gMG)

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Sarada Sakamuri, MD
Sarada Sakamuri, MD
Neuromuscular neurologist, General neurologist, Neurophysiologist
Clinical Assistant Professor, Neurology & Neurological Sciences Clinical Assistant Professor (By courtesy), Neurosurgery

Contact us to find out if this trial is right for you.

CONTACT

SPECTRUM